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Abstract
Background: Patients’ treatment preferences are often cited as barriers to recruitment in randomized controlled
trials (RCTs). We investigated how RCT recruiters reacted to patients’ treatment preferences and identified key
strategies to improve informed decision-making and trial recruitment.
Methods: Audio-recordings of 103 RCT recruitment appointments with 96 participants in three UK multicenter
pragmatic RCTs were analyzed using content and thematic analysis. Recruiters’ responses to expressed treatment
preferences were assessed in one RCT (ProtecT - Prostate testing for cancer and Treatment) in which training on
exploring preferences had been given, and compared with two other RCTs where this specific training had not
been given.
Results: Recruiters elicited treatment preferences similarly in all RCTs but responses to expressed preferences
differed substantially. In the ProtecT RCT, patients’ preferences were not accepted at face value but were
explored and discussed at length in three key ways: eliciting and acknowledging the preference rationale,
balancing treatment views, and emphasizing the need to keep an open mind and consider all treatments. By
exploring preferences, recruiters enabled participants to become clearer about whether their views were robust
enough to be sustained or were sufficiently weak that participation in the RCT became possible. Conversely, in
the other RCTs, treatment preferences were often readily accepted without further discussion or understanding
the reasoning behind them, suggesting that patients were not given the opportunity to fully consider all
treatments and trial participation.
Conclusions: Recruiters can be trained to elicit and address patients’ treatment preferences, enabling those
who may not have considered trial participation to do so. Without specific guidance, some RCT recruiters are
likely to accept initial preferences at face value, missing opportunities to promote more informed decision-making.
Training interventions for recruiters that incorporate key strategies to manage treatment preferences, as in the ProtecT
study, are required to facilitate recruitment and informed consent.
Trial registration: ProtecT RCT: Current Controlled Trials ISRCTN20141297. The other two trials are registered but have
asked to be anonymized.
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Background
Recruitment to randomized controlled trials (RCTs) is
often challenging, with less than 50% of trials estimated
to meet recruitment targets [1]. Patients’ treatment pref-
erences have been frequently cited as a barrier to trial
recruitment [2-5] and clinicians find it difficult to recruit
patients who favor a particular treatment [6-9]. Several
studies have focused on the impact of patients’ treat-
ment preferences on trial recruitment and outcome
[4,10], but there has been little attention to what consti-
tutes a preference and how it should be measured and
handled within a trial setting or in clinical practice.
Several previous studies have tended to assume that
patients’ treatment preferences are simple and static en-
tities that can be easily defined and measured [4,10].
However, there is also a small body of research that
shows that preferences are complex, multifaceted, and
changeable entities that can be based on incomplete or
inaccurate information [11-16]. Within the context of
RCTs, a treatment preference has been defined as ‘the
difference in the perceived desirability of two or more
interventions’ - a relative and potentially quantifiable
concept by which the desirability of one intervention is
compared with another [16]. Within this definition, and
within the wider literature on ‘desirability’, preferences
can be broadly based on expectancies concerning the
process and outcomes associated with the intervention
and the perceived value placed on those outcomes and
processes [16]. Various factors can shape preferences in-
cluding the way in which the information on interven-
tions is presented or ‘framed’ [17-21], prior experience
of treatment [13], and whether or not the treatment is
available outside of the trial [22]. Patient sociodemo-
graphic and health status can also determine treatment
preferences, for example younger patients have been
shown to prefer a more aggressive approach to treat-
ment than older patients [23,24], as do those who have
‘someone to live for’ [25]. The study of preferences is
further complicated by their instability; preferences may
not be fixed and can change as experience of an inter-
vention is gained [16]. In our previous research into the
role of patients’ treatment preferences at trial recruit-
ment, we exposed the difficulty of defining and studying
treatment preference due to the variation in the way it was
expressed between participants and over time, and how it
changed in response to interactions with recruiters [15].
Eliciting patients’ treatment preferences has been pro-
posed as one of the key elements to ensure shared
decision-making in clinical practice [26]. Stiggelbout et al.
state that clinicians should determine patients’ treatment
preferences ‘to judge whether the benefits and risks of
treatments are balanced from the patient’s perspective and
to avoid procedures patients would rather not have if they
are well-informed’ [27]. This approach is also important in
RCT recruitment, where the aim is to give potential re-
cruits sufficient information about the treatment options
within and outside of the trial to make an informed deci-
sion about participation or otherwise [28]. Our previous re-
search in an RCT for localised prostate cancer treatment
(the ProtecT - Prostate testing for cancer and Treatment –
trial), in which recruiters were specifically encouraged to
elicit patients’ treatment preferences and trained in how to
manage them, showed that it was possible to understand
initially-expressed preferences and establish that many were
not well-founded [14,15]. After sensitive exploration of pa-
tients’ treatment preferences many preferences dissipated
sufficiently so that many were open to randomization [15],
leading to higher levels of recruitment with high rates of al-
location acceptance [14,19]. The details of how this was
achieved in the ProtecT trial compared with how prefer-
ences are managed in other trials form the focus of the
present research. The aims were to: (1) compare how treat-
ment preferences were elicited and managed in recruitment
consultations in three contrasting RCTs - two where trial
recruiters did not receive specific training in exploring
them and one (the ProtecT trial) in which recruiters were
trained in how to manage them; and (2) to illustrate how
strategies used by the trained recruiters in the ProtecT
trial might be used to inform methods to optimize trial
recruitment.
Methods
Randomized controlled trials
Trial 1 was undertaken in 11 UK-based hospitals to
compare the effectiveness of three surgical treatments
(traditional surgery versus two minimally invasive proce-
dures) for a vascular condition. Study centers could opt
for a two-arm design (traditional surgery versus one
minimally invasive procedure) if preferred. Patients aged
18 years or older with the condition were referred by
their GP to a routine outpatient clinic consultation with
a surgeon for examination and a decision as to whether
surgical treatment was appropriate. In the context of this
routine outpatient appointment, eligible patients were
informed about the different treatments available and
the RCT. They were provided with patient information
sheets about the trial and treatments to take home
(where possible a summary information sheet was pro-
vided with the clinic invite letter in advance of the main
information sheet). Around a week later a research nurse
would follow-up with a telephone call to ascertain their
willingness to participate in the trial. No specific training
was given in relation to treatment preferences beyond
the standard training for the trial. A qualitative study of
recruitment was initiated in one centre that had opted
for the two-arm trial design and recruitment appoint-
ments over an eight-month-period were audio-recorded
to understand reasons for low levels of recruitment.
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Feedback from this was not given to the trial team until
after the eight-month-period of audio-recording.
Trial 2 was conducted across three centers in the UK
to determine the feasibility of an RCT comparing current
standard non-surgical and surgical treatments for a type
of cancer. Eligible patients aged 18 years or older with a
recent diagnosis were invited to a clinic for a consult-
ation with a surgeon where the two standard treatments
were discussed, the study introduced, and a patient infor-
mation sheet explaining the trial and treatments given. A
week later a second appointment was conducted with an
oncologist for further discussion of the two treatments
and the trial, and to seek consent to participate. The re-
cruiters did not have any specific training regarding how to
deal with patients’ treatment preferences at recruitment.
There was an integrated qualitative study of recruitment
across the three centers, part of which involved audio-
recording all recruitment consultations to monitor them
and address any problems, but formal feedback and train-
ing regarding patients’ treatment preferences had not been
performed at the time of the present study. In one centre
some limited feedback about the content of recruitment
appointments, including how to describe randomization
and balancing of treatment arms, had been given.
Trial 3 (ProtecT) was undertaken in nine UK clinical
centers and compared radical prostatectomy, radical
conformal radiotherapy, and active monitoring in over
1,500 men aged between 50 and 69 years with localised
prostate cancer [29]. Men were given a written patient
information sheet at the time of prostate specific antigen
(PSA) testing and diagnosis informing them of the treat-
ments and the need for an RCT. An audio-recorded
RCT information and recruitment appointment was held
approximately one week after diagnosis with an experi-
enced research nurse using a checklist to ensure essen-
tial information was covered. Nurses received ongoing
training and feedback through training documents, indi-
vidual and group discussions, and role play developed
from findings from earlier qualitative research within the
trial [14,19] to ensure that they provided detailed and ac-
curate information on the study and treatments and to
facilitate recruitment across the centers [14,19,29]. As
part of this training, eliciting and exploring treatment
preferences was actively encouraged to assist men in
reaching an informed decision about trial participation
or the selection of treatment outside the trial.
Data sampling, collection, and analysis
Audio-recordings of recruitment appointments in trials
1 and 2 were scrutinized and those in which participants
expressed a treatment preference were included in the
present study. In trial 3 (ProtecT), a sample of 93 re-
cruitment appointments from all nine study centers
over a three-month-period (taken in year six of the
nine year recruitment period) had already been assessed
in terms of the presence or absence of participant-
expressed treatment preferences [15]. From this sample
we selected all those in which participants voiced a treat-
ment preference at any point in the consultation. We de-
fined a ‘treatment preference’ as any favoring or liking, to
any degree, towards a particular treatment. This may re-
late to aspects of the treatment itself and likely outcomes,
or conversely relate to a dislike of the other treatments.
This definition resulted from the detailed study of prefer-
ences across the 93 trial recruitment appointments in our
previous research [15]. It did not distinguish between
strengths of preference as our previous research demon-
strated that preferences were based on a continuum from
relatively unformed views to clear and justified requests
for a treatment, either of which may develop into stronger
views or dissipate during discussion [15]. To assess the
variation within and across the study groups, participants’
sociodemographic data were obtained from question-
naires, case study reports, and patient medical records.
Audio-recordings of recruitment appointments were
transcribed verbatim, read several times, and a combin-
ation of simple content analysis [30] and more in-depth
thematic analysis [31] applied to the data. Transcripts
were systematically coded, supported by the qualitative
data organization package Atlas.ti (Scientific Software
Development GmbH, Berlin, Germany), according to
how preferences were revealed, the recruiter’s response
to them, and any strategies to address them. A second
experienced social scientist analyzed 10% of the data in-
dependently to compare, discuss, and refine coding to
enhance its reliability. Codes were scrutinized and simi-
lar codes grouped to produce themes using methods of
constant comparison [31]. Data from each trial were ini-
tially analyzed separately and then findings were compared
across the trials to identify differences or similarities. Ana-
lysis was an iterative and cyclical process, each time adding
to or modifying existing codes and going back to previous
transcripts when new themes emerged in order to look for
differences or similarities. Data saturation was considered
to have been reached with the given sample as no new
themes were forthcoming. NM conducted the main ana-
lysis, JD reviewed and contributed to the analytical process,
and data were discussed with the study team.
Ethics approval was obtained in all three trials for the
discussions to be audio-recorded and analyzed for the
purposes of studying the recruitment process, and writ-
ten consent was obtained from all participants (see ‘Ac-
knowledgements’ for details).
Results
Participant and trial details
Basic trial details are shown in Table 1. Of the audio-
recorded recruitment appointments from one study centre
Mills et al. Trials 2014, 15:323 Page 3 of 13
http://www.trialsjournal.com/content/15/1/323
in trial 1, 8 out of 15 participants expressed a treatment
preference, and 14 out of 19 participants from two study
centers in trial 2 voiced a preference in either of the con-
sultations with the surgeons or oncologists (Table 1). In
trial 3 (ProtecT), 74 out of 93 participants from all nine
study centers expressed a treatment preference in recruit-
ment consultations (Table 1). None of the participants in
trials 1 and 2 who expressed an initial preference agreed
to be randomized, compared with 50 out of 74 (68%) in
trial 3. In all three trials preferred treatments were spread
across the different available options. Characteristics of
the study sample are shown in Table 2.
Participants had one or two RCT recruitment consul-
tations, depending on the design of the trial. In trial 1,
the eight participants who expressed a treatment prefer-
ence had a consultation conducted by one of three sur-
geons, and six of these had a follow-up telephone call
from the research nurse to determine their decision to
participate (in the other two cases a decision not to par-
ticipate was agreed at the end of the consultation with
the surgeon). Appointments lasted a median of 16 mi-
nutes ranging from 12 to 48 minutes (follow-up telephone
calls were combined with the recruitment consultations)
(Table 1). In trial 2, the 14 participants had two recruit-
ment consultations. The first was conducted by one of
seven surgeons across the two centers and the second by
one of four different oncologists. Two patients had a fur-
ther appointment with the same oncologist (these consul-
tations were combined for the analysis). A total of 28
consultations with the 14 participants were assessed and a
treatment preference was expressed in 21 of these con-
sultations. Seven of the 14 participants voiced a prefer-
ence in both consultations, one did so only in the
consultation with the surgeon and six did so only in
the consultation with the oncologist. The median length
of the recruitment appointments (combining those
with the surgeon and oncologist) was 64 minutes (range
22 to 99, Table 1). Participants in trial 3 (ProtecT) had
one RCT recruitment appointment ranging from 21 to
120 minutes (median 56 minutes), conducted by one
or occasionally two research nurses in each study
centre (Table 1).
In total, 103 recruitment appointments in which treat-
ment preferences were expressed by 96 participants
across the three RCTs were analyzed in depth to assess
how recruiters responded to these preferences.
Table 1 Comparison of the RCTs’ characteristics and recruitment processes
Trial 1 Trial 2 Trial 3 (ProtecT)
Study interventions Two or three surgical
treatments for a vascular
condition
Surgical and non-surgical
treatment for cancer
Surgery, radiotherapy, and active
monitoring for localised prostate
cancer
Recruiting clinicians Surgeons (with short follow-up
call by research nurse)
1st appt with surgeons,
2nd with oncologists
Research nurses
Number of consultations audio-recorded 15a 38 93b
How many attended a consultation 15 19 93
How many expressed treatment
preference (%)
8 (53%)c 14 (74%) 74 (80%)
Number of consultations where treatment
preference expressed
8 21 74
Number of patients randomized who
originally stated a treatment preference (%)
0 (0%) 0 (0%) 50 (68%)
Median length of consultations in minutes
(range)
16 (12-48) 32 (surgeon), 32 (oncologist),
64 combined (22-99)
56 (21-120)
aConsultations with the surgeons and the follow-up phone call were combined where applicable.
bSample of all recruitment appointments over a three-month-period.
cUnable to assess 7 participants due to incomplete recordings of consultations or follow-up call.
Table 2 Study sample characteristics (n = 96)
Participant characteristics Trial 1 (n = 8) Trial 2 (n = 14) Trial 3 (ProtecT) (n = 74)
n (%) n (%) n (%)
Male gender 5 (63%) 8 (60%) 74 (100%)
Mean age at RCT recruitment appointment in years (SD) 51 (SD 10.8) 66 (SD 7.24) 62 (SD 4.51)
White British ethnicity 7 (88%)a -b 72 (97%)
Married/living as married -b 9 (64%)a 61 (82%)
aOne observation missing.
bData not available.
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How treatment preferences were elicited
In all three RCTs, treatment preferences tended to be
expressed by participants following indirect and often
open styled questions after they had been introduced to
the study treatment options. Questions such as ‘what are
your thoughts at the moment?’, ‘was that [patient infor-
mation sheet] very clear?’, or ‘have you got any questions
to start us off about the treatments?’ tended to elicit a
preference. Treatment preferences were also sometimes
voiced spontaneously as the recruiter began talking about
a particular treatment. The RCT tended to be introduced
early in trial 3 (ProtecT) consultations, as indicated in
their training, but later on in the other two trials. Conse-
quently, preferences in trial 3 consultations were often
expressed comparatively earlier in the appointment.
Recruiters’ responses to expressed treatment preferences
There was a clear difference in how recruiters responded
to the expressed preference between the trials. In trial 1,
participants expressed a treatment preference in either
the appointments with the surgeons or the follow-up
phone calls with the research nurse. Recruiters (mostly
the research nurse at follow-up) readily accepted partici-
pants’ preferences without further discussion and explor-
ation of the reason behind it in all of the eight cases:
‘RESEARCH NURSE: Have you had a chance to look
through the literature you were given in the clinic
about the different treatment options?
A03: Yeah I did....I mean I’d like to go for [minimally
invasive surgical option].
RESEARCH NURSE: Okay that’s fine. I’ll let
[recruiter’s] secretary know that.’
(Trial 1, patient chose preferred treatment)
‘A06: I’ll go for [minimally invasive surgical option]
RESEARCH NURSE: [laughs] Can I let you think
about it and I’ll give you a ring. [At follow up phone
call] Have you had a chance to read the literature I
gave you about the study and the treatment options?
A06: I have yes
RESEARCH NURSE: Okay and what would you like to do?
A06: Um, I think I wanna go with um [minimally
invasive surgical option]
RESEARCH NURSE: Okay.’
(Trial 1, patient chose preferred treatment).
Some participants, unprompted, stated the reason be-
hind wanting a particular treatment, but in half of the
cases the rationale for the preference was not apparent
and it was not possible to know whether they fully
understood the other treatment option or the existence
of the RCT.
In trial 2, preferences were expressed then accepted by
recruiters without any discussion or exploration in 8 of
the 21 consultations. This occurred in both centers and
by a variety of different recruiters. In one of these cases
the recruiter agreed to the participant receiving their
treatment of choice before providing full details on the
treatment, and in another the recruiter actually agreed
with the participant’s treatment choice and in doing so
revealed their lack of equipoise:
‘B08: I made up my mind at the weekend when I read
about the [non-surgical option]. I just don’t want it.
ONCOLOGIST 1: You don’t want it. No, no. That’s fine.’
(Trial 2, study centre 1, patient chose preferred
treatment).
‘B10: Because from what I can gather it’s not that bad,
it hasn’t spread anywhere else. So the chances are
this, this [non-surgical option] could cure it.
ONCOLOGIST 3: That’s absolutely right
B10: You know if it had gone anywhere else I’d, I
would have said straightaway well go for that [surgical
option]….
ONCOLOGIST 3: Yep, yeah I understand that it’s a
worrying time isn’t it. So you would rather go for the
[non-surgical option]?
B10: I think that’s the best thing to do.
ONCOLOGIST 3: Yep ok, that’s absolutely fine…. I
think that’s the right thing to do actually.’
(Trial 2, study centre 2, patient chose preferred
treatment).
There were attempts by the recruiters to address the
expressed preference in the remaining 13 recruitment
consultations by balancing participants’ views on the
study treatments, for example, by stating the disadvan-
tages of their preferred treatment or the advantages of
their less preferred treatment in response to a voiced
preference. They also highlighted the position of clinical
equipoise (not knowing what the best treatment was)
and hence the rationale and importance of the trial:
‘B01: I want rid of it, to have surgery to get it - having
the surgery and getting it cut away…
SURGEON 1: Well, I will tell you honestly that I do
not know which is better and I’m a surgeon but I feel
that - erm, that we need to try to find out which kind
of treatment is better.’
(Trial 2, study centre 1, patient chose preferred
treatment).
However, the discussion did not usually go beyond this
initial counterbalancing and it tended not to be tailored
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to the individual’s specific concerns. In most cases recruiters
accepted the preferred treatment soon after providing the
counterbalanced information, often without discussion of
the underlying rationale for the preference and therefore
understanding of the reason for the preference:
‘ONCOLOGIST 3: Would you be prepared to think
about letting the computer decide whether you have
an op or the [non-surgical] treatment?
B05: Well we’ve had a chat with friends, family and
everybody really and - I think the operation we had
decided, we thought maybe it’s one operation and
that’s it, it’s gone hopefully. We looked at some of the
implications with the [non-surgical option], like you
said they’ve all got complications with whichever one
you have. But I think the operation was the favorite one
ONCOLOGIST 3: So - I - I’m, shall I just give you a
contrary view? Would that be helpful?
B05: Yes, yes.
ONCOLOGIST 3: I’m quite happy if you make that
decision that’s absolutely fine, ok. So there are two
things one the surgery has a very high complication
rate, and the quality of life probably dips more with
surgery than it does with [non-surgical option], ok. It’s
true that you imagine you have the cut and it’s all
over and done with, but in many ways [non-surgical
option] is aiming at having the same effect…… they
each have their pros and their cons and they’re both
very different. And that’s really why we need to do the
trial so you come here and you say well look what’s
the best treatment for me and I can say, well it is -
because at the moment we can’t really do that you see.
[Short discussion omitted with patient’s wife about
being given several treatment options]
ONCOLOGIST 3: Yep. [7 second silence] So you’re
sticking with plan A then [surgery]?
B05: Yes, yeah.’
(Trial 2, study centre 2, patient chose preferred treatment).
In a minority of cases preferences were not simply ac-
cepted by the recruiters straight after providing counter-
balanced information, they continued instead with further
discussion of the treatments and the trial. The recruiters’
responses appeared to have a marked effect - the partici-
pants began to consider other initially less preferred treat-
ment - but they still opted for their preferred choice in the
end. In only one of the 21 consultations in which prefer-
ences were voiced did the recruiter attempt to explicitly
explore the underlying rationale for the preference before
then accepting it:
‘ONCOLOGIST 4: Have you had any thoughts about
it [participating in the trial]?
B12: Well, I’ve had a lot of thoughts about it and it’s
always been a little bit, I don’t know. It’s, I don’t
know, I don’t know. But I’ve eventually, at the
moment anyway, unless I heard something completely
different from somebody - erm, to go for the [non-
surgical option].
[Short discussion omitted on random treatment
allocation]
ONCOLOGIST 4: Ok. You’d rather stick with the
[non-surgical option]
B12: Go with the [non-surgical option], I think. Yes.
ONCOLOGIST 4: So, do you want to tell me why
that is?
B12: Not really because, erm I don’t know enough
about it to be able to, sort of, give you a - a, sort of,
serious thing. I just feel that I’d rather, sort of, go for
that than - than the surgery part - it’s as simple as
that.
ONCOLOGIST 4: Ok. What, in particular puts you
off the surgery?
B12: Erm, I’m not particularly - I don’t think I’m
particularly worried about surgery, as such, erm, but I
think - well, [sighs] the surgery, as I understand it,
would be, sort of - cut up here, sort of, to one thing
get that out and then two more places as well to move -
and I think, well, is - if the [non-surgical option] can
do the same thing without the cutting that’s my only
reason, really [in picking it].
ONCOLOGIST 4: Ok. That’s fair enough.’
(Trial 2, study centre 2, patient chose preferred
treatment).
In this trial (trial 2), preferences were more commonly
expressed in the second appointment with the oncologist
than in the first consultation with the surgeon, likely in
part because participants had had time to absorb the in-
formation and formulate a view. However, oncologists
were more likely than surgeons to readily accept a pref-
erence at face value and not explore it; oncologists ac-
cepted a preference without discussing it further in 6
out of 13 consultations compared with only 2 out of 8
consultations with surgeons in which preferences were
not pursued. Consultations appeared independent of
each other in terms of discussion of treatment prefer-
ences; having voiced, and in some cases discussed, a treat-
ment preference in the first appointment with the surgeon
did not appear to affect whether the oncologist in the sec-
ond appointment explored the patient’s preference or ac-
cepted it at face value. As with trial 1, all of those who
expressed a treatment preference in trial 2 declined trial
participation in favor of their preferred treatment.
Analysis of recruitment appointments in trial 3 (Pro-
tecT) revealed much further exploration and discussion
of expressed treatment preferences overall. Participants
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often came to the appointment with a particular treatment
in mind. The expressions of treatment preferences were
not dissimilar to those in other consultations but it was
the recruiters’ response to them that differed. There was
only one case in which the recruiter readily accepted the
participant’s preference without further discussion of it, in
a similar way to those in trials 1 and 2. In this case the
man offered a clear rationale for his preference and this
was accepted without exploration by the recruiter. In all of
the other 73 cases, however, the recruiters did not readily
accept the participant’s preference but explored it further.
Although the nurse recruiters had a checklist of infor-
mation to cover in the recruitment appointments, the
way they actually structured the consultation in response
to a preference voiced early on varied. Some recruiters
acknowledged the preference and then discussed the
three study treatments, exploring and addressing the
preference as part of this process. These consultations
tended to be more structured and led predominantly by
the recruiter [17]. In other consultations, recruiters
started by exploring the preference, using this to discuss
the treatments in more depth, in appointments that
tended to be more loosely structured and led mostly by
the participant [17].
Exploration of preferences
Three key techniques were used by recruiters in trial 3
(ProtecT) in response to participants’ treatment prefer-
ences, all of which were indicated in their training [14].
Details of these techniques are given below. The num-
bers indicate the order in which techniques tended to be
used, although this did vary especially in the consulta-
tions that were more loosely structured. Not all ap-
proaches were used in each consultation but at least one
approach was used, and often the recruiters employed
multiple approaches.
1. Elicit and acknowledge the rationale for the
preference
When participants voiced a preference for a particular
treatment the most frequent response from recruiters was
to establish the basis for it. Justifications for preferences
were often given without direct prompting, but where they
were not stated or were unclear, recruiters would seek to
understand them with direct questioning, such as ‘Is there
any particular reason why you think that way is better than
the other ways?’ or ‘Why do you think like that?’. Once a
rationale was established, recruiters moved on to explore
and discuss the underlying reasons and beliefs:
‘RESEARCH NURSE: I know that [surgery] is your
least [preferred] treatment. Is it the fear of an
operation, going through surgery, or are there things
that you’d like to discuss that I might be able to
perhaps relieve some anxieties about surgery?’
(Trial 3, study centre 9, patient chose initial
preference).
This more detailed exploration of the basis of the pref-
erence revealed reasons that were multilayered and com-
plex, usually internally rational and logical, and sometimes
guided by lay perceptions of prostate cancer and the avail-
able treatments. For example, favoring radical therapy to
‘get [the cancer] all away’ or desiring conservative treat-
ment because ‘if it’s not broke don’t fix it’. Some rationales
were more emotive than scientifically based, for example,
relating to the experiences of relatives who had died from
cancer. These discussions provided the recruiter with use-
ful information to tailor information provision to address
patient concerns.
2. Balance participants’ views about treatment
After ascertaining the basis for the preference, recruiters
would usually acknowledge these reasons, but then indi-
cate that they should still go through information about
all treatments to ensure that participants had the neces-
sary information to make an informed decision:
‘RESEARCH NURSE: I appreciate what you say about
monitoring and if at the end of this discussion if that’s
what you feel, we will support you whatever you want
to do… But before you do that I need to go through
your results with you because you’ve got to be entirely
clear what your results mean… there are things about
the treatments, that you may not have considered…in
all the positive sides about the treatments you have to
know what the down sides are as well..…you have to
be able to know in your own heart, that you have
explored every angle....whatever decision you make
you know that you will have had all the information
about these treatments for you to make that decision.’
(Trial 3, study centre 9, patient randomized to initially
less desired option and accepts it).
Recruiters then provided information to balance partici-
pants’ views about treatments by highlighting the disad-
vantages of the preferred treatment and advantages of the
less desired treatments, as some recruiters did in trial 2:
‘C01: I’ve achieved my aim as in I’ll still stick to the
monitoring.
RESEARCH NURSE: How will you feel about the
psychological effects of monitoring? Have you thought
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about how that will affect you mentally? The cancer’s
still there, its’ not gone away, we haven’t removed it. I
need to find out that part because the, all of our men
who are on monitoring it’s the biggest problem.’
(Trial 3, study centre 1, patient chose initial
preference).
‘RESEARCH NURSE: Now the thing with surgery is,
yes it’s a potential cure, you’re quite right about that,
but the problem with it is that umm it is a major
procedure.’
(Trial 3, study centre 4, patient randomized to initial
preference and accepts it).
They further encouraged participants to consider a
balanced view of the treatments by tailoring information
to their needs, for example, providing reassurance to al-
leviate specific concerns and correcting inaccuracies
about treatment:
‘C89: There’s no way I can do that [continue with his
caring commitments] after this [prostate] operation....
RESEARCH NURSE: Right well I mean we can help
with that sort of thing.... we do put things in place to
help the men when they’re out of hospital. So you
know, don’t discount that immediately.......’
(Trial 3, study centre 3, patient randomized to initial
preference and accepts it).
‘RESEARCH NURSE: So [I’ll] talk about the
radiotherapy next
C19: Oh dear, this is the worst one
RESEARCH NURSE: Is it? Why- why d’ya think it’s
the worst one?
C19: I- I’ve got a brother-in-law, he jus- (−) he’s had
lots of trouble with his throat [had cancer of the
throat]. And he- he’s lost his teeth, hearing’s gone and,
err, he’s in a hell of a state......Because it don’t just [radiate]
the (−) affected zone but it sort o- ‘cause the beam seems
as though it sprays a bit an’ it, err, destroys everything
RESEARCH NURSE: .....Now (−) yes, there is always
that chance that that can- th- that the radiotherapy is
gonna hit the surrounding tissue ...... But, these
symptoms tend to be worse towards the end of the
treatment, ok, and then start to improve….. We
want to reduce the side effects and the risks of the
surrounding soft tissue, so, by doing -, you know,
having the- the hormone treatment, it helps us to- to
be more precise with the radiotherapy..... Now, what
you’ve got to remember is, your brother-in-law has had
a very different type of cancer.... your teeth are not
going to fall out with this one, nor is your hair or
anything like [that] and we are looking for precision.’
(Trial 3, study centre 7, patient randomized to initially
less desired option and accepts it)
They also highlighted the position of clinical equipoise
to counterbalance participants’ views, emphasizing that
although all treatments offer equally good survival rates
but with different side-effect profiles, there was a lack of
evidence to support a clear choice between them:
‘C05: That’s the one, the monitoring. Mainly because
I’ve only got a small, microscopic, yeah and I think
it’d be best for me, uh, to have that, to come back
every two or three months. And if it does get any
worse, then I would gladly have the operation.
RESEARCH NURSE: Well, unfortunately, it doesn’t
quite work like that..... the thing is, we don’t know the
best way to treat prostate cancer and the three
treatments that we have, in terms of how long men
live, are all equal. So it doesn’t matter which
treatment you have, men tend to live, you know, their
life expectancy out. All three of them have advantages
and disadvantages to them. And if we knew what was
best for you, that’s what you would get. But we don’t
know that.’
(Trial 3, study centre 3, patient randomized to initially
less desired option and accepts it).
3. Emphasize need for participant to consider all
treatments and equipoise
Recruiters expressed empathy with the difficult situ-
ation of clinical equipoise, particularly with men who
were struggling with the decision. Throughout the con-
sultation in response to a voiced preference they empha-
sized the need for participants to try to keep an open
mind about each of the treatments to allow them to
weigh up the advantages and disadvantages and decide if
they could consider being randomized or not:
‘WIFE: My son wants him to have the operation, get
rid of it
C50: But as you’ve said, if it ain’t that big....
RESEARCH NURSE: We don’t know…there’s such a
dilemma about the whole thing.... because they can’t
answer that question which is the best .... we know
that they are as good as each other the treatments
and that’s the important thing. But each have
advantages and disadvantages that are different from
each other because they are very different treatments.
And it’s just weighing up those, and then stepping
back from that, so being open minded about each of
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the treatments is important because as I say they are very
different from each other…. looking at it and saying, well
will I at least consider any one of those three treatments
as an option for me and then saying if that’s yes to that
then let the computer pick the treatment for you, or
there’s one that you really hate, let’s kind of discuss it
some more or no I’d rather choose my own treatment.’
(Trial 3, study centre 1, patient randomized to initial
preference and accepts it).
Recruiters checked participants’ level of equipoise with
open questions such as ‘what are your feelings at the
moment?’ to determine their openness to randomization.
There was often evidence of the participant expressing
the rationale for his preference and the recruiter offering
information in response to enable them to consider a
balanced view, with checking of their position in relation
to equipoise and the suggestion of randomization, at
various points. This form of dialogue enabled men to re-
consider their original preference and learn more about
the other treatments. For some, this led to a sustained
and confident treatment choice, but many shifted away
from their original preference and became increasingly
uncertain or equivocal [15]. Some participants even
chose a treatment that was different from their originally
expressed preference [15]. The appointment continued
until the recruiter was satisfied that the participant was
sufficiently equivocal and prepared to consider all the
treatments to permit randomization, or was felt to be in-
formed enough to choose a particular treatment.
Two extracts from appointments illustrate how these key
techniques were used together by recruiters in the ProtecT
trial in response to a voiced treatment preference. In the
first extract we see the recruiter eliciting the man’s con-
cerns with his less preferred treatment options and then
providing information to put these concerns into perspec-
tive. The recruiter further encourages a balanced view of
treatments by checking he is comfortable with the poten-
tial drawbacks of his preferred treatment. Likewise, in the
second example the recruiter offers balanced information
in response to a preference by emphasizing the advantages
of the less preferred treatment, and later by emphasizing
the position of clinical equipoise and uncertain prognosis
following his concerns for the less preferred treatment. In
both cases the recruiters ascertain the men’s position
of equipoise (twice with C85) and when it is clear what
the man’s position is, a treatment is either chosen (as
in the first extract) as the preference has been sus-
tained, or randomly allocated (as in the second extract)
as the preference has dissipated and the man is accept-
ing of all treatments:
C78: I’m definitely veering towards the monitoring
side of things, because why have all those additional
complications, the potential for them… I’ve got a
good quality of life and I would like it to continue.....
RESEARCH NURSE: So what would be your worry
with surgery?
C78:…With surgery there could be complications…
the catheter and impotence.
RESEARCH NURSE: …It’s difficult to say…the
majority of men won’t have those problems… What’s
so worrying about radiotherapy?…
C78: Well it can affect other areas like the bladder.
RESEARCH NURSE: Hmm that’s usually very short
term.
C78: Is it?.....
RESEARCH NURSE: Can I just ask, how do you think
you would feel if you go for the monitoring, the one
you’re drawn to, if your PSA was creeping up a bit cos
it’s not something that you know from one blood test
we can’t suddenly decide..... and I wonder how that
would be you know sort of, kind of waiting, the blood
test and all that?..... [Further discussion about
drawbacks of PSA monitoring]
RESEARCH NURSE: So the idea of all treatments -
they’re not equal to you in anyway?
C78: No…
RESEARCH NURSE: Whatever you decide, as long as
you’ve had all the information.
C78: Oh I’ve got all the information.’
(Trial 3, study centre 9, patient chose initial preference).
C85: If I went in for the operation…. then you’ve got
the recovery, then you’ve got this that and the other
[side effects] and then I think I’m better to leave it
[have active monitoring]
RESEARCH NURSE: The guarantee with that
[surgery] I would say is that they would get rid of the
prostate cancer ….. you get that reassurance because
you know it’s gone, the cancer’s gone [Discussion
continues about all treatments and the trial]
Wife: Oh as he walked through the door he was
definitely [opting for] monitoring….
RESEARCH NURSE: How do you feel [now]?
C85: I don’t know, when does the decision actually
have to be made? [Discussion about the trial/
randomization]
C85: Doesn’t it say in that you could be cracking a
walnut with a sledgehammer and you might be-
RESEARCH NURSE: Could be but we don’t know
that you see…this is the thing we might need a
sledgehammer we just don’t know, that’s the problem
[Continue discussion about treatments and the trial/
randomization]
C85:.... I didn’t know the implications, therapies…
because to be honest I just put that on the back
burner…. this has been very informative….
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RESEARCH NURSE: So how do you feel then, what
are we going to do?
C85: I’m, I’m happy with all three so to me it would
seem a crying shame not to take part in this work
today…well, well they’ve all got their pluses, they’ve all
got their minuses…I haven’t got a preference as such
you know they’re all equal. [Randomized and told
allocation] To be honest I would have been ok with
any.
(Trial 3, study centre 3, patient randomized to initial
preference and accepts it).
Discussion
This study has detailed, for the first time, how recruiters
deal with patients’ treatment preferences in three differ-
ent RCTs, including one where recruiters were trained
and supported to elicit and explore treatment prefer-
ences. The means by which preferences were elicited did
not differ greatly between the three trials; there was ei-
ther a simple indirect open styled question that revealed
the patient’s preference, or a preference was voiced un-
prompted after the introduction of a treatment. There
were, however, very clear differences in how recruiters
responded to the expressed preferences. In the ProtecT
RCT (trial 3), trained recruiters explored the preferences
and enabled participants to become clearer about whether
their views were robust enough to be sustained or were
sufficiently weak that participation in the RCT became
possible [15]. Most were open to randomization following
exploration of their preferences. In the other two trials,
preferences were often accepted at face value without fur-
ther discussion and exploration of the underlying rationale
for the treatment choice. No participants who expressed a
preference in these trials were randomized. This study has
illustrated how key techniques, provided as part of a
training package [14], have been implemented by trial
recruiters to elicit and explore patients’ treatment pref-
erences in recruitment discussions to improve levels of
informed consent and consideration of trial participa-
tion. Such techniques could be further evaluated in a
comparative study and form the basis for training and
empowering recruiters to explore preferences in future
trials.
A recent systematic review of the recruitment activity
of clinicians across a variety of RCTs highlighted the
need for training, concluding that understanding and
communicating RCT methods was a priority for future
interventions to improve recruitment [32]. Findings from
a survey and workshop of UK Clinical Research Collabor-
ation registered clinical trial unit directors confirmed
these findings, identifying methods for improving recruit-
ment and in particular training for site staff as the highest
priority for trials methodology research [33]. Although
trial recruiters perceive patients’ treatment preferences as
a barrier to recruitment [6-9], a recent synthesis of the
perspective of 72 recruiters from six RCTs revealed clear
obstacles and hidden challenges relating to their dual roles
as clinicians and recruiters that led to their discomfort in
approaching and discussing trials with patients [9,34]. The
study found that recruiters were more likely to accept pa-
tients’ treatment preferences at face value without further
exploration rather than offer recruitment to the RCT if
that preference accorded with their own views, and
highlighted the need for recruiter training and support,
particularly in the management of treatment preferences
[9]. Findings from the current study support these conclu-
sions and offer suggestions in how to better manage treat-
ment preferences.
In the past, it has been assumed that preferences make
recruitment difficult [35], and that ‘challenging’ prefer-
ences may be considered to be coercive [36]. This re-
search shows that recruiters can be trained to elicit and
address patients’ treatment preferences during RCT re-
cruitment appointments, and that they do this more
often than those without this specific training, and that
this can lead to an increase in the numbers of patients
who then consider and accept recruitment to the RCT
[14,15,19]. The justification for exploring patients’ treat-
ment preferences at trial recruitment should be to gauge
their level of understanding of all treatment options to
ensure that their decision whether to participate or not
in the trial is well-informed. This is the ethical basis for
preference exploration and this gauging of understand-
ing should occur even if the patient enters the recruit-
ment appointment in a position of equipoise, as they
may have a weak or misinformed basis for their position.
The process of recruitment is a socially delicate, inter-
actional undertaking, with subtle moments in appointments
influencing participants’ understandings and willingness to
participate [37]. Despite this, very little research has focused
on the content of the interactions that lead to informed con-
sent and RCT participation. A small number of studies have
shown that doctors can struggle to explain RCTs clearly
[38,39], that shared decision-making is not always practiced
[40], that some participants take part because of altruism
[41], and some seem unaware that they are involved in re-
search [42]. Recordings of recruitment appointments can
permit an open debate about whether the exploration of pa-
tients’ treatment preferences should be considered coercive
or an informative part of gaining fully informed consent,
and where a line might be drawn. We did not assess the im-
pact of preference exploration from the patients’ perspective
because the focus of our study was on recruitment appoint-
ments, and so it will be important to include patients’ per-
spectives of recruitment and preference exploration in
future research. These issues are complex and will need to
balance formal ethical guidance with increasing demands by
patients to be fully informed.
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One of the challenges with training recruiters to com-
municate the concept of clinical equipoise and to spend
time understanding patients’ preferences is the impact
on the time taken in consultations in which consent to
participate is sought. In this study, appointments con-
ducted by research nurses in trial 3 (ProtecT), who were
supported to explore patients’ preferences, were longer
(56 minutes on average) than those conducted by sur-
geons and the research nurse in trial 1 (16 minutes), al-
though similar to the combined appointments with
oncologists and surgeons in trial 2 (64 minutes). The dif-
ference in time between trials 1 and 3 may be explained
by the simpler nature of trial 1’s interventions for a non-
life threatening condition, but may also be due to the
extra time taken to understand patients’ treatment pref-
erences in trial 3. Whilst longer consultations may lead
to increased costs, the costs of trial extensions, closures,
or trials never being undertaken because it is thought to
be too difficult to recruit need to be considered and
compared with the costs of training clinicians to recruit
effectively, a skill which is likely to be transferable be-
tween RCTs. Consideration should also be given to who
is best placed to recruit trial participants. A nested RCT
in the ProtecT feasibility study showed that trained re-
search nurses were as effective as doctors at recruiting
to the trial and more cost-effective [43], but nurses can
also experience difficulty with recruitment [9,37]. It has
yet to be formally assessed if doctors can be trained to
explore treatment preferences as consistently as the
trained research nurses in the ProtecT study.
Although the ways recruiters responded to patients'
preferences were different between trial 3 (ProtecT) and
the other trials, it is possible that the observed differ-
ences were related to factors other than the specific
training. There were, for example, differences across the
trials in terms of the seriousness of the condition, the
risk profile of the treatments, and the backgrounds and
numbers of recruiters. Trial 1 offered the least invasive
treatments with relatively low-risk profiles for a non-life
threatening condition, with one research nurse doing
most of the actual recruiting. In this trial, preferences
were readily accepted without exploration which may be
a reflection of the relative ‘mildness’ of the condition
and low-risk profile of both treatment options. However,
it may also reflect the previously identified discomfort
and difficulties that nurses may have with trial recruit-
ment (and in particular treatment preferences) in rela-
tion to their perceived roles as a caring clinical nurse
[9]. Trial 2, in contrast, offered recruitment by surgeons
and oncologists to a trial with more complex treatments
for a potentially life-threatening condition, with diverse
and potentially debilitating side effects. Despite these dif-
ferences with trial 1, a sizeable proportion of recruiters
also showed a similar ready acceptance of preferences,
and those that did not accept immediately did not ex-
plore the underlying rationale for the treatment choice,
missing opportunities to promote more informed decision-
making. These findings were in contrast to the research
nurses who were trained in trial 3 to sensitively explore
treatment preferences.
It must also be acknowledged that the RCTs compared
here might not be representative of RCTs in general and
that they were a ‘convenience’ sample. Trial 1 sought ex-
ternal help with recruitment after experiencing difficul-
ties, and trial 2 included an integrated qualitative study of
recruitment from the outset, but the data presented here
were collected before any training on patients’ treatment
preferences had been given in these trials. The issue of
generalization or transferability of findings should be con-
sidered in light of the number of audio-recordings ana-
lyzed, particularly in the comparator trials. The number of
available audio-recordings in trial 1 was relatively small.
This trial also relied on data from only one study centre
and with the same research nurse following up on patients
to determine their willingness to be randomized. These is-
sues suggest that caution in interpretation of findings may
be warranted, however, similar findings were observed in
the other comparator trial (trial 2) where a larger number
of consultations were analyzed from a variety of clinicians
across two study centers. As most trials do not routinely
audio-record their trial recruitment consultations, access
to such data is limited.
A strength of the study was the range of qualitative
analyses undertaken on ProtecT trial data [9,15,17,34,37]
and the availability of audio-recorded data of recruit-
ment appointments across three different trials. These
permitted the identification of key aspects that can lead
to improved recruitment (more patients sufficiently in-
formed to consider participation and higher recruitment
rates). Methods for eliciting preferences, ascertaining
and acknowledging their rationales, balancing partici-
pants’ views about treatment, empathy with the difficult
situation of clinical equipoise, and retaining an open
mind to all treatments, could be developed into training
programs to be used in other trial contexts. The strat-
egies need to be combined with simple communication
techniques, such as using open questions, long pauses,
and readily ceding the floor [17], along with detailed
considerations of how to avoid coercion. Previous re-
search suggests that training oncologists in effective
communication styles and behaviors may positively im-
pact upon RCT recruitment [44]. The question remains
of how much training recruiters should receive to effect-
ively explore treatment preferences to facilitate recruitment
and informed consent - whether simple encouragement is
sufficient or whether more detailed training, monitoring,
and feedback on communication skills and implementation
of key strategies is required.
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Findings here support suggestions now being made in
usual clinical practice to diagnose patients’ treatment
preferences and engage patients in discussion to improve
informed decision-making [45]. However, doctors are
not routinely trained to address patients’ treatment pref-
erences. Communication skills required by clinicians
needed to explore preferences are not often the focus of
consultations in everyday practice, therefore it is not sur-
prising that clinicians are not routinely addressing pref-
erences within the context of trial recruitment. The key
techniques identified in this study to address treatment
preferences could be applied outside of the trial context
to usual clinical care.
Conclusions
In conclusion, these data show that: (1) it is possible to
train trial recruiters to elicit and address patients’ treat-
ment preferences to help them to consider participation
in the trial; and (2) they do this more consistently than
recruiters who do not receive this type of training. With-
out specific training and guidance, recruiters are likely
to accept initial preferences without understanding the
reasoning behind them. This can result in recruiters
missing opportunities to correct inaccuracies in under-
standing and potentially denying patients the opportun-
ity to fully consider all treatments and trial participation.
This study has described three key techniques that re-
cruiters can use rather than simply accepting expressed
preferences at face value. Eliciting and exploring treat-
ment preferences, if done sensitively, can enable patients
to consider issues inherent in the RCT more fully, in-
cluding the position of clinical equipoise and aspects
that they may have misunderstood, and thus enable
them to more fully consider RCT participation.
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